Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
Funding: The study was funded by the National Clinical Research Centre for Cardiovascular Diseases (NCRC2022001).
Disclosures: Doctor Yuan reports that all authors declare no relevant conflicts of interest.
References and notes:
1‘The TOP-CABG trial’ presented during HOT LINE 10 on 1 September 2025 at 14:21 to 14:31 in Madrid (Main Auditorium).
2Xenogiannis I, Zenati M, Bhatt DL, et al. Saphenous vein graft failure: From pathophysiology to prevention and treatment strategies. Circulation. 2021;144:728−745.
3Sandner S, Redfors B, Angiolillo DJ, et al. Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: A systematic review and meta-analysis. JAMA. 2022;328:554–562.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
The hashtag for ESC Congress 2025 is #ESCCongress
Follow European Society of Cardiology News on LinkedIn
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.